20 January 2020 - Mayzent (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis with active disease in Europe.

Novartis today announced the European Commission has approved Mayzent (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features of inflammatory activity. Although every patient’s MS journey is unique, up to 80% of relapsing remitting MS patients will eventually transition to SPMS4. Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did not have an oral treatment that has been shown to be effective in delaying progression in this patient population. 

The European marketing authorisation makes Mayzent the first and only indicated oral treatment proven in SPMS patients with active disease based on a randomised clinical trial of a broad range of SPMS patients.

Read Novartis press release